Bank of New York Mellon
INMB icon

Bank of New York Mellon’s INmune Bio INMB Stock Holding History

Bank of New York Mellon’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.6K Sell
21,229
-32,399
-60% -$44.8K ﹤0.01% 4252
2026
Q1 		$60.6K Sell
53,628
-4,893
-8% -$6.97K ﹤0.01% 4137
2025
Q4 		$91.3K Sell
58,521
-1,330
-2% -$2.37K ﹤0.01% 4109
2025
Q3 		$124K Sell
59,851
-1,753
-3% -$4.01K ﹤0.01% 4084
2025
Q2 		$142K Buy
61,604
+6,681
+12% +$49K ﹤0.01% 4038
2025
Q1 		$429K Buy
54,923
+4,521
+9% +$35.9K ﹤0.01% 3523
2024
Q4 		$235K Buy
50,402
+850
+2% +$4.43K ﹤0.01% 3890
2024
Q3 		$267K Sell
49,552
-9,048
-15% -$64.3K ﹤0.01% 3821
2024
Q2 		$517K Buy
58,600
+32,511
+125% +$320K ﹤0.01% 3571
2024
Q1 		$307K Sell
26,089
-7,311
-22% -$88.3K ﹤0.01% 3763
2023
Q4 		$376K Buy
33,400
+509
+2% +$4.27K ﹤0.01% 3704
2023
Q3 		$223K Buy
+32,891
New +$273K ﹤0.01% 3923

Other funds holding INMB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Bank of New York Mellon's INMB Position: Q2 2026 in Review

Bank of New York Mellon reduced its INmune Bio (INMB) stake by 60% in Q2 2026, selling an estimated $44.8K and leaving 21,229 shares worth $34.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4252.

Bank of New York Mellon first reported a position in INMB in Q3 2023 and has held it in 12 quarters since. The position peaked at $517K in Q2 2024. 38 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Bank of New York Mellon held 21,229 shares of INmune Bio worth $34.6K as of Q2 2026.
  • Bank of New York Mellon sold 32,399 INmune Bio shares in Q2 2026, an estimated $44.8K.
  • INmune Bio made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4252 holding.
  • Bank of New York Mellon first reported a position in INmune Bio in Q3 2023 and has held it in 12 quarters since.
  • Bank of New York Mellon's INmune Bio position peaked at $517K in Q2 2024.
  • 38 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.